Park Medi World IPO Proceeds Utilization: Monitoring Report for Q4 2025 Released
Park Medi World Limited's IPO proceeds utilization report for Q4 2025 shows ₹5,328.30 crore unutilized funds. During the quarter, ₹1,430.90 crore was used for loan repayment and ₹795.00 crore for acquisitions, including KP Institute of Medical Sciences and Krishna Super-speciality Hospital. Total IPO funds were ₹7,700 crore.
This is a standard regulatory filing detailing the utilization of IPO funds. It does not introduce any new material information that would significantly impact the company's stock or operations.
The report is a routine disclosure of IPO proceeds utilization and does not contain any positive or negative financial performance indicators or future outlooks.
Park Medi World Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, detailing the utilization of its Initial Public Offering (IPO) proceeds. The report, issued by CRISIL Ratings Limited, was reviewed and considered by the Board of Directors and Audit Committee on February 13, 2026.
The company's IPO, which raised ₹7,700 million (gross proceeds), allocated funds towards repayment of outstanding borrowings (₹3,800 million), funding capital expenditure for a new hospital by subsidiary Park Medicity (NCR) (₹605 million), purchase of medical equipment (₹274.59 million), and unidentified inorganic acquisitions and general corporate purposes (₹2,453.18 million). Additionally, ₹567.23 million was earmarked for issue expenses.
During the quarter ended December 31, 2025, Park Medi World Limited utilized ₹1,430.90 million for repayment of borrowings by its subsidiaries. A significant portion of ₹795.00 million from the general corporate purposes allocation was used for part-funding acquisitions: ₹495.00 million for KP Institute of Medical Sciences (via KPS Wellness Private Limited and SVPD Healthcare Private Limited), ₹250.00 million for Krishna Super-speciality Hospital (via Mahip Hospitals Private Limited), and ₹50.00 million for Devina Derma Private Limited (via Aggarwal Hospitals and Research Services Private Limited). Issue expenses incurred during the quarter amounted to ₹145.80 million.
As of December 31, 2025, the total unutilized IPO proceeds stood at ₹5,328.30 million. The report indicates no deviation from the objects disclosed in the Offer Document and confirms that all utilization was as per the disclosures. The company has also transferred issue proceeds of ₹924.98 million from its Monitoring account to its current account for operational ease, including reimbursement of ₹129.98 million for prior issue expenses and ₹795.00 million for the acquisitions mentioned above.
What to do with a filing like this
Park Medi World Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Park Medi World Limited. Read the original for the full detail.